Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Increasing awareness and shift towards personalized therapies
3.2.1.3 Technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of precision medicine
3.2.2.2 Complex regulatory approval process
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Breast cancer
5.3 Lung cancer
5.4 Blood/ hematologic cancer
5.5 Gastrointestinal cancer
5.6 Skin cancer
5.7 Bladder cancer
5.8 Head & neck squamous cell cancer
5.9 Cervical cancer
5.10 Other cancer types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Intravenous
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Molecule Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Small molecules
7.3 Biologics
Chapter 8 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Kinase inhibitors
8.3 Immune checkpoints inhibitors
8.4 Enzyme inhibitors
8.5 Other drug classes
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 AbbVie
10.2 AstraZeneca
10.3 Bayer
10.4 Blueprint Medicines Corporation
10.5 Bristol-Myers Squibb Company
10.6 Eli Lilly and Company
10.7 F. Hoffmann-La Roche
10.8 GlaxoSmithKline
10.9 Merck
10.10 Novartis
10.11 Organon
10.12 Pfizer
